Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004876 | 0.89 | TLR7 (0.44) | TLR7NR4A2HPGDSLMNAGABRA5 | |
| SCHEMBL4762022 | 0.88 | TLR7 (0.43) | TLR7NR4A2HPGDSLMNAGABRA5 | |
| SCHEMBL6003997 | 0.82 | HDAC3 (0.40) | TLR7NR4A2HPGDSGABRA5POLB | |
| SCHEMBL6004394 | 0.82 | ENPP2 (0.42) | TLR7HPGDSLMNASCN9A | |
| SCHEMBL6004885 | 0.82 | TLR7 (0.41) | TLR7HPGDSLMNAGABRA5CNR1 | |
| SCHEMBL4828522 | 0.81 | CHEK1 (0.40) | TLR7SCN9A | |
| SCHEMBL6003993 | 0.80 | TLR7 (0.39) | TLR7HPGDSLMNAGABRA5CNR1 | |
| SCHEMBL4868034 | 0.80 | TGFBR1 (0.49) | TLR7HPGDSCNR1 | |
| SCHEMBL4760698 | 0.77 | ACKR3 (0.48) | — | |
| SCHEMBL4762959 | 0.74 | GABRA5 (0.48) | TLR7LMNAGABRA5CNR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | TLR7 495/4885NR4A2 1163/4885HPGDS 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.